E-7050: Petition to the Government of Canada — Canadian Petition Tracker
Track petition E-7050 — "Petition to the Government of Canada" sponsored by Peter Schiefke. 1,843 signatures and counting. See signature growth trends and provincial breakdown on PetitionTracker.ca.
Canonical URL: https://petitiontracker.ca/petition/e-7050
Petition Details
- Status: Closed
- Closing date: April 20, 2026
- Sponsor: Peter Schiefke (Vaudreuil)
- Category: Health
Signature Statistics
- Total signatures: 1,843
- Daily increase: +23 in the last 24 hours
- Seven-day increase: +106 over the last 7 days
- Growth velocity: ~15 new signatures per day (7-day average)
- Tracking started: March 25, 2026 — 115 data points recorded
Provincial Distribution
- Ontario: 800 signatures
- British Columbia: 363 signatures
- Alberta: 238 signatures
- Quebec: 228 signatures
- New Brunswick: 60 signatures
- Nova Scotia: 46 signatures
- Saskatchewan: 38 signatures
- Manitoba: 20 signatures
- Newfoundland and Labrador: 19 signatures
- Yukon: 4 signatures
Historical Signature Growth
| Date | Signatures |
|---|
| March 25, 2026 | 1,540 |
| April 1, 2026 | 1,548 |
| April 2, 2026 | 1,621 |
| April 2, 2026 | 1,640 |
| April 2, 2026 | 1,663 |
| April 3, 2026 | 1,680 |
| April 5, 2026 | 1,691 |
| April 6, 2026 | 1,702 |
| April 9, 2026 | 1,717 |
| April 9, 2026 | 1,729 |
| April 15, 2026 | 1,741 |
| April 17, 2026 | 1,768 |
| April 19, 2026 | 1,817 |
| April 20, 2026 | 1,843 |
Petition Text
Petition to the Government of Canada
Whereas:
• ALK-positive lung cancer afflicts Canadians who are often younger and have never smoked, and frequently involves a stage IV diagnosis that is devastating to patients and families;
• Lorlatinib is a Health Canada–approved, targeted therapy with demonstrated survival benefits. As a convenient oral medication it allows patients to keep working, caring for families, contributing to their communities, and living their lives. Currently, it is only covered if it is the first treatment taken;
• Access to lorlatinib as a second treatment or later remains cost-prohibitive for Canadians without public coverage, forcing patients to forgo effective therapy, and often resulting in early death;
• Timely access to lorlatinib improves outcomes, reduces symptoms and avoids high-cost interventions (such as hospitalizations); and
• Lorlatinib in the second line is approved by 25 major regulators worldwide (incl. UK, US, Australia), with health-system evaluations finding it a high-value option.
We, the undersigned, citizens and residents of Canada committed to equitable, evidence-based cancer care, call upon the Government of Canada to:
1. Work with the Canadian Drug Agency, the Institut national d’excellence en santé et en services sociaux, provincial and territorial health tables, to ensure public coverage of lorlatinib for ALK-positive lung cancer in the second-line and ulterior settings across Canada;
2. Establish clear, timely, and evidence-based access pathways for precision oncology medicines so that therapies with demonstrated clinical benefit are funded equitably; and
3. Table a report to the House outlining the steps taken and timelines to achieve equitable national access to lorlatinib.
Similar Petitions